Blackstone president directs capital to AI cancer research

Blackstone President John Gray, together with his wife Mindy Gray, is directing increasing amounts of capital — both through Blackstone's own investments and through personal scientific philanthropy — toward cancer research utilizing artificial intelligence, Bloomberg reports.

What is known about the Gray family's strategy

According to Bloomberg, John Gray, who heads Blackstone Inc. — the world's largest alternative asset management company with assets under management exceeding one trillion dollars — is consistently increasing the share of AI investments in the firm's portfolio. Simultaneously, he and his wife Mindy Gray are applying the same principle to personal scientific philanthropy, where the focus is also on applying artificial intelligence in biomedical research aimed at combating oncological diseases.

• John Gray is the president of Blackstone Inc., the world's largest alternative asset manager
• Investment direction — Blackstone investments and personal scientific philanthropy of the Gray family
• Focus of philanthropy — applying AI in research aimed at preventing and treating cancer

Why AI is becoming a tool in oncology

Artificial intelligence is increasingly being applied in biomedicine: models are capable of analyzing huge volumes of genomic and clinical data, predicting protein structure and behavior, accelerating the search for new drug candidate molecules, and finding patterns in diagnostic images that are difficult for the human eye to notice. These are the tasks — accelerating therapy development and more accurate early diagnosis — that are typically the focus of philanthropy combining AI and cancer research, rather than simply funding traditional laboratory grants.

The interest of major investors like the Gray family in this combination reflects a broader trend among capital managers and their families: money from large funds and their leaders is increasingly flowing not only into AI infrastructure — data centers, chips, cloud computing — but also into applied AI developments for medicine and fundamental science. Such philanthropy often becomes a kind of testing ground: promising AI approaches that have shown results in non-commercial research projects subsequently attract commercial venture financing.

Blackstone itself is already known for major bets on the physical infrastructure that stands behind AI: in 2021, the firm acquired QTS Realty Trust, a data center operator, and has continued increasing investments in data centers and energy capacity necessary for their operation since then. Transferring similar logic — seeking growth points where artificial intelligence is changing entire industries — into the Gray family's personal philanthropy looks like a continuation of the same investment philosophy, but now applied to science and medicine rather than real estate and infrastructure.

Such philanthropy is typically structured differently from venture investments: it funds earlier and riskier scientific ideas that are not yet ready to attract classical startup capital, but if successful, are capable of determining the direction of an entire field of medicine for decades — from early diagnosis to personalized therapy tailored to the specific patient's genes.

What this means

When leaders of the world's largest investment companies transfer AI investment logic from business to personal philanthropy, this is yet another signal that the application of artificial intelligence in medical research is perceived by major capital not as an experiment but as a promising and priority direction for years to come.